Newsfile Corp
17 Aug 2026, 11:40 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
OS Therapies expects to be eligible for a Priority Review Voucher (PRV) upon BLA approval for OST-HER2, noting a recent market sale of such vouchers for $220 million. — A PRV represents a massive potential non-dilutive cash windfall relative to the company's current quarterly losses.
+0.80The company is seeking BLA under the Accelerated Approval Program and equivalent European/UK authorizations for OST-HER2 in the second half of 2026. — Regulatory submission for a lead asset is a primary value inflection point for clinical-stage biotech companies.
+0.60OS Therapies has secured capital and expected tax refunds (approx. $8.2M total) providing a financial roadmap into 2027. — Extending the cash runway reduces immediate bankruptcy risk and the need for highly dilutive equity raises.
+0.40Continue reading
6 related stories
Search tags
The company reported a second quarter net operating loss of $8.576 million, an increase from $4.839 million in the prior year quarter. — Accelerating losses indicate higher burn rates, which increases pressure on fundraising and regulatory success.
-0.30The MHRA granted a waiver for the Pediatric Investigation Plan (PIP) requirement for the OST-HER2 request in the UK. — Removing a regulatory requirement simplifies the path to approval and reduces associated costs/time in one jurisdiction.
+0.20Which stocks this story touches
The company secured funding for a roadmap into 2027 and is making regulatory progress with OST-HER2, despite an increase in quarterly operating losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
24/7 Wall Street
20m ago
